Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
Top Cited Papers
Open Access
- 10 March 2017
- journal article
- research article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 76 (6), 1093-1102
- https://doi.org/10.1016/j.jaad.2016.12.014
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasisJournal of the American Academy of Dermatology, 2015
- Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of PsoriasisJAMA Dermatology, 2015
- The cost of biologics for psoriasis is increasingDrugs in Context, 2014
- Canadian Guidelines for the Management of Plaque Psoriasis: OverviewJournal of Cutaneous Medicine and Surgery, 2011
- Guidelines of care for the management of psoriasis and psoriatic arthritisJournal of the American Academy of Dermatology, 2008
- Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)British Journal of Dermatology, 2007
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive reviewPharmacology & Therapeutics, 2007
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJournal of the American Academy of Dermatology, 2007
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978